Pharmacyte BiotechPMCB
13F holders, Q3 2024 (September 30)26holders −2
2new positions
3sold out
1famous investor
$1.91avg. 13F price*
At the end of Q3 2024, 26 institutions reported holding Pharmacyte Biotech Inc. (PMCB) in their 13F filings, down 2 from Q2 2024. 2 opened new positions and 3 sold out. The largest holders were K2 Principal Fund, L.P. ($400K), Vanguard Group Inc. ($367K) and Geode Capital Management, LLC ($321K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Pharmacyte Biotech Inc.
- CUSIP
- 71715X203
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $72 |
| Exits | 3 | $55K |
All 13F filers, Q2 2024 → Q3 2024: 5,442 shares bought and 198,249 shares sold, net −192,807 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 26 holders
| K2 Principal Fund, L.P. | 0.20% | Reduce -36.1% | 209,266 | $400K |
| Vanguard Group Inc. | 0.00% | No change | 192,387 | $367K |
| Geode Capital Management, LLC | 0.00% | Reduce -4.8% | 168,200 | $321K |
| Equitec Proprietary Markets, LLC | 1.45% | No change | 82,727 | $158K |
| Renaissance Technologies | 0.00% | Add +2.5% | 49,700 | $95K |
| Susquehanna International Group, LLP | 0.00% | Reduce -35.8% | 35,228 | $67K |
| Dimensional Fund Advisors LP | 0.00% | Add +7.8% | 27,601 | $53K |
| Schonfeld Strategic Advisors LLC | 0.00% | Add +9.3% | 25,900 | $49K |
| Northern Trust Corp. | 0.00% | No change | 19,208 | $37K |
| UBS Group AG | 0.00% | Reduce -69.7% | 8,354 | $16K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -61.3% | 2,860 | $5K |
| Acadian Asset Management LLC | 0.00% | No change | 2,851 | $5K |
| Aspire Private Capital, LLC | 0.00% | No change | 800 | $2K |
| Osaic Holdings, Inc. | 0.00% | Reduce -1.0% | 508 | $969 |
| Bank of America Corp. | 0.00% | Reduce -23.0% | 117 | $223 |
| Planning Capital Management Corp | 0.00% | No change | 100 | $191 |
| Maryland Capital Advisors Inc. | 0.00% | New | 35 | $68 |
| JPMorgan Chase & Co. | 0.00% | Reduce -5.3% | 18 | $34 |
| Sachetta, LLC | 0.00% | No change | 14 | $28 |
| Bfsg, LLC | 0.00% | No change | 5 | $10 |
| Morgan Stanley | 0.00% | Reduce -33.3% | 2 | $5 |
| Jones Financial Companies LLLP | 0.00% | New | 2 | $4 |
| NewEdge Advisors, LLC | 0.00% | No change | 2 | $4 |
| Royal Bank of Canada | 0.00% | Reduce -61.7% | 100 | $0 |
| Cwm, LLC | 0.00% | No change | 1 | $0 |
| Covestor Ltd | 0.00% | No change | 226 | $0 |
"% of holder's portfolio" is PMCB's weight in each manager's 13F, not the share of Pharmacyte Biotech Inc. the manager owns.